“…Estazolam and triazolam impaired learning, recall, and performance on the repeated acquisition procedure, digit entry and recall task, and DSST as a function of dose. These findings systematically replicate previous reports that used these measures to assess the behavioral effects of anxiolytichypnotic-sedative compounds including alprazolam (Bickel, Hughes, & Higgins, 1990;Evans, Troisi, & Griffiths, 1994;Mumford et al, 1995aMumford et al, , 1995b, abecarnil (Mumford et al, 1995a), diazepam (Bickel, Higgins, & Griffiths, 1989, Bickel et al, 1990Desjardins, Moerschbaecher, Thompson, & Thomas, 1982;Higgins, Bickel, O'Leary, & Yingling, 1987;Higgins & Stitzer, 1990), lorazepam (Roache & Griffiths, 1987;Rush et al, 1993a), pentobarbital (Kirk et al, 1990;Roache & Griffiths, 1985), temazepam (Rush et al, 1993b;Rush & Griffiths, 1996), triazolam (Bickel et al, 1990;Evans et al, 1990;Kirk et al, 1990;Rush et al, 1993aRush et al, , 1993bRush & Griffiths, 1996), secobarbital (Higgins & Stitzer, 1990), and zolpidem (Evans et al, 1990;Rush & Griffiths, 1996). Estazolam and triazolam also increased participant-rated strength of drug effect and observer-rated sedation, which is consistent with the profile of effects produced by anxiolytic-hypnotic-sedative drugs (e.g., Evans et al, 1990;Rush et al, 1993aRush et al, , 1993b This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.…”